Título:	Genetic alterations of SMYD4 in solid tumors using integrative multi-platform analysis
Autor(es):	Santana, Brunna Letícia Oliveira Loyola, Mariana Braccialli de Gualberto, Ana Cristina Moura Silva, Fabio Pittella
ORCID:	https://orcid.org/0000-0002-7816-764X https://orcid.org/0000-0002-9644-7098
Afiliação do autor:	University of Brasília, Faculty of Healthy Sciences, Laboratory of Molecular Pathology of Cancer University of Brasília, Faculty of Healthy Sciences, Laboratory of Molecular Pathology of Cancer University of Brasília, Faculty of Healthy Sciences, Laboratory of Molecular Pathology of Cancer University of Brasília, Faculty of Healthy Sciences, Laboratory of Molecular Pathology of Cancer
Assunto:	Metiltransferases Epigenética Câncer Mutação genética
Data de publicação:	Mai-2024
Editora:	MDPI
Referência:	SANTANA, Brunna Letícia Oliveira et al. Genetic Alterations of SMYD4 in Solid Tumors Using Integrative Multi-Platform Analysis. International Journal of Molecular Sciences, [S. l.], v. 25, n. 11, 6097, 2024. DOI: https://doi.org/10.3390/ijms25116097. Disponível em: https://www.mdpi.com/1422-0067/25/11/6097. Acesso em: 10 ago. 2026.
Abstract:	SMYD4 is a member of the SMYD family that has lysine methyltransferase function. Little is known about the roles of SMYD4 in cancer. The aim of this study is to investigate genetic alterations in the SMYD4 gene across the most prevalent solid tumors and determine its potential as a biomarker. We performed an integrative multi-platform analysis of the most common mutations, copy number alterations (CNAs), and mRNA expression levels of the SMYD family genes using cohorts available at the Cancer Genome Atlas (TCGA), cBioPortal, and the Catalogue of Somatic Mutations in Cancer (COSMIC). SMYD genes displayed a lower frequency of mutations across the studied tumors, with none of the SMYD4 mutations detected demonstrating sufficient discriminatory power to serve as a biomarker. In terms of CNAs, SMYD4 consistently exhibited heterozygous loss and downregulation across all tumors evaluated. Moreover, SMYD4 showed low expression in tumor samples compared to normal samples, except for stomach adenocarcinoma. SMYD4 demonstrated a frequent negative correlation with other members of the SMYD family and a positive correlation between CNAs and mRNA expression. Additionally, patients with low SMYD4 expression in STAD and LUAD tumors exhibited significantly poorer overall survival. SMYD4 demonstrated its role as a tumor suppressor in the majority of tumors evaluated. The consistent downregulation of SMYD4, coupled with its association with cancer progression, underscores its potential usefulness as a biomarker.
Unidade Acadêmica:	Faculdade de Ciências da Saúde (FS) Departamento de Farmácia (FS FAR)
Programa de pós-graduação:	Programa de Pós-Graduação em Ciências Médicas
Licença:	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
DOI:	https://doi.org/10.3390/ijms25116097
Aparece nas coleções:	Artigos publicados em periódicos e afins

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.